We bring you the latest news from the healthcare about the health care in the United Kingdom.

woensdag 10 oktober 2018

WHO: Committing to End TB in Children, Adolescents and Families

Committing to End TB in Children, Adolescents and Families
On the eve of the 73rd UN General Assembly, UNICEF, WHO and the Stop TB Partnership hosted a side-event to show commitment and accelerate action towards ending TB in children, adolescents and families. Co-sponsored by the Permanent Mission of Japan to the United Nations, the Danish Ministry of Health, the Permanent Mission of Nigeria to the United Nations, TB Alliance, Louder Than TB, Treatment Action Group, Unitaid, the Global Fund, USAID, Elizabeth Glaser Pediatric AIDS Foundation, JHPIEGO, The Union, KNCV Tuberculosis Foundation and Every Woman Every Child, the event aimed to show commitment and accelerate action towards ending TB in children, adolescents and families. Leaders and people affected by TB discussed the importance of targeted commitments for children and adolescents. During the event the new Roadmap towards ending TB in children and adolescents was launched.

The event was opened by Stefan Peterson (Chief of Health Section, UNICEF Head Quarters), Tereza Kasaeva (Director Global TB Programme, WHO) and Lucica Ditiu (Executive Director, Stop TB Partnership). They highlighted the current global epidemiology of TB in children and adolescents, progress made since the publication of the first childhood TB Roadmap and the remaining gaps around case detection, prevention and integration of services aimed at children and adolescents.
Read more

Q&A on the investigational vaccine candidate M72/AS01E
M72/AS01E is a subunit vaccine comprised of an immunogenic fusion protein (M72) derived from two Mycobacterium tuberculosis (M.tb) antigens (MTB32A and MTB39A), and the GlaxoSmithKline (GSK) proprietary adjuvant AS01E. AS01E is the same adjuvant used in Shingrix GSK vaccine, as well as in the new malaria vaccine RTS,S/AS01E.

The M72/AS01E vaccine candidate is being developed by the pharmaceutical company GlaxoSmithKline, in partnership with AERAS. AERAS is a not for profit organization based in the US, aimed at supporting tuberculosis vaccine research, funded by the Bill and Melinda Gates foundation, the UK Department for International Development (DFID), and other organizations.
Read more